Product logins

Find logins to all Clarivate products below.


Binge Eating Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Binge Eating Disorder (US)

Binge eating disorder (BED) is a prevalent condition in the United States; it affects millions of individuals across diverse demographics. BED is characterized by recurrent episodes of excessive food consumption, leading to significant emotional and physical distress. Effective treatment often involves a combination of psychotherapy (e.g., cognitive behavioral therapy [CBT]) and medications such as lisdexamfetamine and antidepressants. However, BED remains underdiagnosed due to stigma and low awareness. Addressing these challenges through public education and healthcare training can improve diagnosis and treatment outcomes, while ongoing research may lead to more-effective therapies. In this report, we assess drug usage patterns in BED based on U.S. patient-level claims data.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed BED patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed BED patients?
  • How has lisdexamfetamine (Vyvanse, generics) been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of BED patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of BED patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Key drugs covered

bupropion, lisdexamfetamine (Vyvanse; generics), semaglutide, SSRIs, topiramate

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Key features

Dashboard featuring interactive visuals, easy navigation, and expanded analyses.

Real-world data

Longitudinal patient-level claims data analysis

Key analyses

  • Brand / therapy usage across longitudinal patient sample
  • Newly diagnosed patient analysis
  • Treatment initiation and progression
  • Line of therapy analysis
  • Combination therapy analysis
  • Source of business for recently treated patients
  • Persistency and compliance analysis
  • Product-level patient flow charts

Related Market Assessment Reports

Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Gene Therapy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. The pipeline…
Report
Epilepsy – Landscape & Forecast – Disease Landscape & Forecast (G7)
Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…
Report
Dry Eye – Landscape & Forecast – Disease Landscape & Forecast (G7)
Dry eye disease (DED) is characterized by the loss of tear film homeostasis, caused by the inadequate production or the rapid evaporation of tears. The DED market is evolving rapidly, driven by…
Report
Asthma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The asthma therapy market consists of many well-established drugs, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva…